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INTRODUCTION
Despite the fact that tuberculosis is a curable disease, it is 
one of the ten causes of death in the world [1]. There was 
a decrease in the incidence of tuberculosis in Ukraine, in 
2019 (from 62.3 to 60.1 per 100 thousand of the popula-
tion) and mortality (from 9.4 to 8.8 per 100 thousand of 
the population) from this disease. At the same time, the 
incidence of children increased by 1.1%, and the incidence 
of adolescents – by 5.3% [2]. At the same time, the rate of 
increasing the effectiveness of treatment of TB patients 
in Ukraine is insufficient to achieve the WHO target (by 
2025 there should be 90% of patients who have successful 
treatment). Among patients with sensitive tuberculosis, 
about 77% had effective treatment. Only 49% of patients 
with multidrug-resistant tuberculosis (MDR-TB) had a 
satisfactory treatment outcome. Only 37% of patients with 
extended resistance (XDR-TB) were successfully cured [1].
The authors had a research involving 796 patients with 
tuberculosis. It was found that the main barriers to tuber-
culosis treatment in Ukraine encompass structural barriers 
associated with the organization of the health care system 
and the unregulated regulatory framework, barriers at the 
level of anti-tuberculosis institutions and the general route 
of the patient between different branches of health care, 
gaps in interaction between health workers and patients, 
individual factors, including social, economic and psy-
chological consequences of treatment for the patient [1].
However, there is insufficient data on the pathogenesis of 
tuberculosis, depending on the sensitivity of the pathogen 
and the characteristics of the proteolytic system.
THE AIM
Studying the features of the proteolytic system in patients 
with tuberculosis depending on the sensitivity of the 
pathogen.
MATERIALS AND METHODS
In the study, we examined 111 patients who were divided 
into three groups. The first group consisted of 66 (59.5%) 
people with pulmonary tuberculosis (PTB) – (Table І). 
The second group included 13 (11.7%) patients with tu-
berculous pleurisy (PLTB). The third group consisted of 
32 (28.8%) patients with dual localization of the process 
(pulmonary tuberculosis and pleural tuberculosis) – (PTB-
PLTB). The main last group consisted of 23 healthy individ-
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ABSTRACT
The aim: Studying the features of the proteolytic system in patients with tuberculosis depending on the sensitivity of the pathogen.
Materials and methods: In the course of the research we studied the level of elastase in the blood of 111 patients. The first group consisted of 66 (59.5%) people with 
pulmonary tuberculosis (39 were sensitive to antibacterial drugs, 27 were resistant). The second group included 13 (11.7%) patients with tuberculous pleurisy. The third group 
consisted of 32 (28.8%) patients with dual localization of the process (pulmonary tuberculosis and pleural tuberculosis).
Results: The level of neutrophil elastase in patients with tuberculous pleurisy (253.2 nmol / min • ml) was 2.2 times higher than in patients with sensitive pulmonary tuberculosis 
(110.1 nmol / min • ml) and higher than in patients with resistant pulmonary tuberculosis 3.0 times. In combined pulmonary and pleural tuberculosis (third group) the level 
of elastase was 1.6 times higher than in pulmonary tuberculosis (176.9 nmol / min • ml)) (p <0.01), but lower than in pleurisy in 1, 4 times. In sensitive combined tuberculosis 
(lungs and pleura) the level of NE was 1.5 times higher than in patients of subgroup 1a (p <0.01) and 1.4 times lower than in patients with tuberculous pleurisy (p <0.01 ). 
Conclusions: The highest level of elastase in tuberculous pleurisy can be explained by its increased production, contributes to increased “permeability” of the pleural sheets 
and the accumulation of pleural effusion. In resistant forms of tuberculosis, the immune response in the form of the activity of the proteolytic system, which is lower than in 
sensitive forms, can be explained by the exhaustion of the immune system under the influence of aggressive tuberculosis. The above can be associated with both the weakening 
of the patient’s body and the aggressiveness of the pathogen.
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uals who had no lung or pleural disease at the time of the 
examination and had not been ill in the past. Among the 
examined control group there were 11 women and 12 men.
When studying the sensitivity of the mycrobacterium 
tuberculosis (MBT) to antibacterial drugs, it was found that 
out of 39 (59.1%) people on PTB had preserved sensitivity 
of mycobacteria to first-line drugs. These patients were 
assigned to subgroup 1a. The other 27 (40.9%) patients 
had MDR-TB, that is, resistant to the two main first-line 
anti-TB drugs: isoniazid and rifampicin. These patients 
were assigned to subgroup 1b. Among patients of subgroup 
1b, in addition to the MBT resistance to rifampicin and 
isoniazid, resistance to ethambutol was found in 17 (63.0%) 
patients, to pyrazinamide in 13 (48.1%) patients, and in all 
100.0% of patients to streptomycin. In addition, resistance 
to kanamycin, capreomycin and amikacin was found in 4 
(14.8%) patients, 7 (25.9%) and 17 (63.0%), respectively. 
Resistance to levofloxacin was stated in 7 (25.9%) patients, 
to ofloxacin – in 6 (22.2%) and to moxifloxacin in 7 (25.9%) 
subjects. Thus, in 7 patients, in addition to MBT resistance 
to rifampicin and isoniazid, a combination with one of 
the injectable drugs and one of the fluoroquinolones was 
established. So, the expanded resistance of MBT to anti-
bacterial drugs in patients of the first group occurred in 
25.9% of those studied.
In the second group, all 13 (100.0%) patients were di-
agnosed with pleural TB with preserved sensitivity to the 
first-line drugs (by the genetic molecular method using 
the GeneXpert apparatus).
Among patients of the third group (PTB-PLTB) patients 
with pulmonary and pleural tuberculosis sensitive to an-
ti-tuberculosis drugs predominated – 22 (68.8%), which 
were designated as subgroup 3a. There were 10 patients 
(31.2%) with resistant tuberculosis, which were assigned 
to subgroup 3b. In this subgroup (3b) in addition to resis-
tance to isoniazid and rifampicin in 7 (70.0%) there was 
resistance to ethambutol, in 9 (90.0%) – to streptomycin, 
in 2 (20.0%) – to pyrazinamide, 1 (10.0%) – to capreomy-
cin, kanamycin, ofloxacin moxifloxacin and ethionamide. 
Extended resistance occurred in 2 (20.0%) people. 
In general, among the studied patients of all groups, 
tuberculosis sensitive to antibacterial drugs was stated in 
74 (66.7%) patients, resistant – in 37 (33.3%) people.
The study of the proteolytic system was carried out by 
determining the activity of neutrophil elastase in the blood 
serum of patients by the spectrophotometric method, 
preliminarily freeing it from the complex with a protein-
ase inhibitor using Tris-HCl buffer. N-BOC-L-Alanine 
p-nitrophenyl ester was used as a substrate according to a 
known technique [3].
Table І. Distribution of examined patients according to the sensitivity of the pathogen
Group patients
Sensitive Resistant Total
quantity % quantity % quantity %
The first 39 59,1 27 40,9 66 59,5
The second 13 100,0 - 100,0 13 11,7
The third 22 68,8 10 31,2 32 28,8
Total 74 66,7 37 33,3 111 100,0
Table ІІ. The level of neutrophil elastase in patients of the first group
Indicator
Groups of patients
1а group (n=39) 1б group (n=27)









values Average value 75,0
35,2-215,1 110,1±11,8*,# 34,6-163,1 78,4±9,2*
Note:
* – statistically confirmed differences between the indicators of patients of groups I and II (p<0,05);
# – statistically confirmed differences between the indicators of the studied patients and the control group (p<0,01);
& – according to previous studies [4]. 
Table ІІІ. The level of neutrophil elastase in patients of the second group
Indicator
Patients with pleurisy
(n=13) Control group 
(n=23)
Range Average value
Neutrophil elastase, nmol / min • ml 144,7 – 350,5 253,2±16,7* 75,0
* – statistically confirmed differences between the indicators of the study of patients and the control group (p<0,01).
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This research was approved by the Ethics Committee 
of Sumy State University, Sumy, Ukraine (Protocol № 2, 
03.11.2020). Research was conducted keeping to the main 
issues of the Convention of the Council of Europe on Hu-
man Rights and Biomedicine of Declaration of Helsinki of 
the World Medical Association on the ethical principles 
of conducting medical research involving human beings 
(1975, with further amendments, including version of 
2000) and Order of Ukrainian Ministry of Health № 690 
on 23.09.2009.
Statistical processing of the material was carried out 
using licensed software products included in the Microsoft 
Office Home & Business 2016 package (license X20-34344-
01) on a personal computer Everest in Excel program by the 
method of variation statistics using the Student’s test. The 
difference in indicators was considered reliable at p <0.05.
RESULTS AND DISCUSSION
We compared the level of neutrophil elastase (NE) in pa-
tients of both subgroups with the level of NE in relatively 
healthy individuals who at the time of the study had no 
diseases and had no lung diseases in the past (Table ІІ). It 
was found that in patients with sensitive forms of pulmo-
nary tuberculosis, the level of elastase ranged from 35.2 
to 215.1 nmol / min • ml, on average it was 110.1 ± 11.8 
nmol / min • ml. The level of NE in patients of subgroup 
1a (110.1 ± 11.8) exceeded its value in healthy individuals 
by 1.5 times, which is significantly higher than its values 
in healthy individuals (p <0.01). In patients with mul-
tidrug-resistant tuberculosis (subgroup 1b), the level of 
elastase ranged from 34.6 to 163.1 nmol / min • ml with 
an average value of 78.4 ± 9.2 (p <0.05). The level of NE 
in patients of subgroup 1b exceeded its value in healthy 
individuals by 1.1 times, but this difference was insignif-
icant (p> 0.05). 
At the same time, the level of elastase in patients sensitive 
to antibacterial drugs pulmonary tuberculosis exceeded its 
level in patients with multi-resistant forms of tuberculosis 
by 31.7 nmol / min • ml, or 1.4 times (p <0.05). 
In the second group, all 13 studied patients sensitive 
to antibacterial drugs pleurisy had a level of neutrophil 
elastase, which ranged from 144.7 – 350.5 nmol / min • 
ml (Table ІІІ). The mean value of elastasis was 253.2 ± 16.7 
nmol / min • ml. In the case of the control group, the level 
of elastase were 3.4 times larger. Compared with the first 
(PTB) group, the level of elastase was 2.2 times higher than 
in subgroup 1a (pulmonary tuberculosis is sensitive to anti-
biotic therapy). That is, the level of neutrophilic elastase in 
patients with tuberculous pleurisy was significantly higher 
than in patients with pulmonary tuberculosis (p <0.01) and 
more than in individuals from the control group (p <0.05).
Among the patients of the third group, who were diag-
nosed with sensitive tuberculosis (subgroup 3a), the level 
of NE fluctuated within 62.5 – 309.8 nmol / min • ml, on 
average it was 176.9 ± 17.4 nmol / min • ml, then there is 
2.4 times more than in the control group (p <0.01). Among 
the subjects of this group, in which there was resistant tu-
berculosis to antibacterial drugs (subgroup 3b), the level 
of NE was in the range of 62.5 - 291.4 nmol / min • ml, ie 
the average value of the indicator was not at the level of 
173.8 ± 26.9 nmol / min • ml, which is 2.3 times more than 
in the control group (p <0,01). The average level of NE in 
subgroup 3a was 176.9 nmol / min • ml practically did not 
differ from the level of NE in subgroup 3b – 173.8 nmol / 
min • ml (p> 0.05) - (Table IV).







Control group  
(n = 23)
Neutrophil elastase,  






62,5-309,8 176,9±17,4* 62,5-291,4 173,8±26,9*
* – statistically confirmed differences between the indicators of the studied patients and the control group (p <0,01).
Table V. Comparison of the level of NE depending on the sensitivity of the pathogen
Study groups
The average value of NE, nmol / min • ml
Sensitive to antibacterial drugs 
tuberculosis, subgroup «a»
Resistant to antibacterial drugs 
tuberculosis, subgroup «b»
Group І 110,1±11,8 85,3±10,7
Group II 253,2±16,7 -
Group III 176,9±17,4 173,8±26,9
Total 155,7±10,4* 109,3±12,4*
* – statistically confirmed differences between the indicators of the studied patients (p <0,01).
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We compared the level of NE in patients of different 
groups with susceptible tuberculosis (Table V). In persons 
of subgroup 3a the level of NE was 1.6 times higher than in 
patients of subgroup 1a – 110.1 nmol / min • ml (p <0.01) 
and 2.3 times less than in patients of group II – 253.2 nmol / 
min • ml (p <0.01). 
We also compared the level of elastase in multidrug-re-
sistant tuberculosis in patients with PTB and PTB – PLTB 
(Table V). The level of NE in subgroup 3b differed sig-
nificantly from subgroup 1b. Thus, in subgroup 1b of the 
subjects the level of NE was 85.3 nmol / min • ml, and in 
subgroup 3b was 173.8 nmol / min • ml, ie it was 2 times 
higher (p <0.01).
The results show that in patients with pulmonary and 
pleural tuberculosis, sensitive to antibacterial therapy, the 
level of elastase significantly exceeded in those who did 
not have at the time of examination and in the past lung 
and pleural diseases. In pulmonary tuberculosis it was 1.6 
times higher, and in patients with tuberculous pleurisy 3.4 
times higher than in the control group. At the same time, 
when combining pulmonary tuberculosis with pleural, the 
level of elastase was 2.4 times higher than in the control 
group. Thus, the most active proteolytic system was in 
isolated pleural tuberculosis, and the pulmonary process 
significantly reduced this activity. In pulmonary tubercu-
losis, the activity of the proteolytic system was even lower.
Resistance of Mycobacterium tuberculosis in specific pa-
tients (multidrug-resistant tuberculosis) affected proteolyt-
ic activity by inhibition in patients of all groups (Table V). 
CONLUSIONS
1)  The level of neutrophil elastase in patients with tuber-
culous pleurisy is 2.2 times higher than in patients with 
pulmonary tuberculosis (110.1 nmol / min • ml) and 
higher than in combined pulmonary and pleural tuber-
culosis (176.9 nmol / min • ml) 1.4 times (p <0.01). This 
can be explained on the one hand by the greater “use” 
of elastase in pulmonary forms of tuberculosis, and on 
the other – increased production of it in pleural tuber-
culosis, which contributes to increased “permeability” 
of the pleural leaves. 
2)  The level of neutrophil elastase in the combined process 
(lungs and pleura) is 2.4 times higher than in the control 
group, but almost no different from sensitive forms of 
pulmonary tuberculosis.
3)  With sensitive joint tuberculosis (lungs and pleura), 
the level of NE was 1.5 times higher than in patients of 
subgroup 1a (p <0.01) and 1.4 times less than in patients 
with tuberculous pleurisy (p <0.01). 
4)  In multidrug-resistant pulmonary tuberculosis, the level 
of NE (85.3 nmol / min • ml) was 2 times lower than in 
combined tuberculosis (lungs and pleura) (p <0.01). In 
resistant forms of tuberculosis, the immune response, 
in the form of activity of the proteolytic system, is lower 
than in sensitive forms, which can be associated with 
both the weakness of the body as a whole and the ag-
gressiveness of the pathogen. 
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